(Q39533858)

12 September 2017

title

NRTI backbone in HIV treatment: will it remain relevant? (English)

1 reference

12 September 2017

Randall Tressler

1

1 reference

12 September 2017

Catherine Godfrey

series ordinal

2

1 reference

12 September 2017

publication date

1 November 2012

1 reference

12 September 2017

1 reference

12 September 2017

volume

72

1 reference

12 September 2017

issue

16

1 reference

12 September 2017

page(s)

2051-2062

1 reference

https://scigraph.springernature.com/pub.10.2165/11640830-000000000-00000

12 September 2017

exact match

0 references

cites work

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Differential effects of nucleoside analogs on oxidative phosphorylation in human pancreatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Mitochondrial myopathy caused by long-term zidovudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Three postpartum antiretroviral regimens to prevent intrapartum HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Renal function with use of a tenofovir-containing initial antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11640830-000000000-00000

Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

12 December 2020

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

1 reference

12 December 2020

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

1 reference

12 December 2020

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children

1 reference

12 December 2020

A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results

1 reference

12 December 2020

Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

1 reference

12 December 2020

Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection

1 reference

12 December 2020

10.2165/11640830-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

1008333640

0 references

1 reference